Participants will receive a free physical exam, laboratory tests and all food during the study. Personal results and an evaluation will be given when the study is completed. Postmenopausal women age 35 and older who may be at increased risk for breast cancer are invited to participate. Tamoxifen is approved by the FDA for the prevention of breast cancer in women who are at increased risk. Raloxifene has been approved by the FDA for the prevention of osteoporosis in postmenopausal women, and may have a breast cancer prevention benefit.
Compensation is provided.
We welcome your suggestions and comments. If you are aware of a resource we should include, please submit it through Feedback . Home Copyright 1996-2001 Info. All rights reserved. Privacy Policy .